EGFR and non-small cell lung carcinoma: ADAURA was a phase III trial of osimertinib daily for three years compared to the placebo, in the adjuvant setting for patients with Stage IB-IIIA resected NSCLC with confirmed common EGFR mutations (exon 19 deletion or exon 21 L858R point mutation).